BioCentury
ARTICLE | Company News

Catalent, Triphase deal

October 10, 2016 7:00 AM UTC

Catalent granted Triphase exclusive, worldwide rights to cancer candidate CD22-4AP. Catalent will receive an upfront payment and is eligible for development and commercialization milestones, plus roy...